NOBIVAC® PUPPY DP
For the active immunisation of young puppies against canine distemper and canine parvovirus disease.
NOBIVAC® PUPPY DP
Reg. No. G2323 (Act 36/1947)
Namibia Reg. No. V97/24.1/888 [NS2]
This vaccine may only be used by persons registered in terms of section 23(1)(c)
of the Veterinary and Para-Veterinary Professions Act, 1982 (Act no. 19 of 1982).
For the active immunisation of young puppies against canine distemper and canine parvovirus disease.
TARGET SPECIES
Dogs
STORAGE INSTRUCTIONS
- Store in a dark place between 2 °C and 8 °C.
- Do not freeze.
- Avoid prolonged or repetitive exposure to high ambient temperatures.
- Allow the vaccine to gradually reach room temperature (20 °C to 25 °C) prior to use.
- Protect from direct sunlight.
- The diluent may be stored at room temperature.
COMPOSITION
It is a combination of live attenuated strains of canine distemper virus and canine
parvovirus grown in cell-line tissue culture and presented as a freeze-dried plug.
Each vial contains a single dose for reconstitution.
CONTENTS
Each vial contains canine distemper virus, strain Onderstepoort ≥ 105 TCID50 and canine parvovirus, strain 154 ≥ 107 TCID50.
WARNINGS
- Destroy any unused vaccine as well as all vaccine containers in accordance with local waste disposal regulations.
- Do not store partially used containers for future use, and use the entire contents when opened.
- The vaccine should be reconstituted using Nobivac® Diluent immediately prior to use.
- Accidental self-injection may lead to severe allergic reactions. Consult a physician.
- KEEP OUT OF REACH OF CHILDREN AND UNINFORMED PERSONS.
- Although this remedy has been extensively tested under a large variety of conditions, failure thereof may ensue as a result of a wide range of reasons. If this is suspected, seek veterinary advice and notify the registration holder.
PRECAUTIONS
- Only healthy puppies should be vaccinated and an adequate clinical examination should be made prior to inoculation.
- Observe aseptic precautions. Ensure that vaccination equipment (needles, syringes, etc.) are clean and sterile prior to use.
- Avoid contamination of the vaccine with traces of disinfectant and spirits.
- Avoid intravenous injection.
- Hypersensitivity reactions, following administration are rare but as with all vaccines it may occasionally be encountered. In this event administration of adrenaline injection by the subcutaneous route may be indicated.
- It is good vaccination practice when handling the vaccine to avoid contact with the eyes, hands and clothing.
DIRECTIONS FOR USE – USE ONLY AS DIRECTED
- Puppies should be vaccinated with a single dose of Nobivac® Puppy DP at 4 to 6 weeks of age, preferably before weaning.
- Puppies which have received Nobivac® Puppy DP should be further immunised with Nobivac® DHPPi, 3 to 4 weeks later.
DOSAGE AND ADMINISTRATION
The contents of 1 vial of reconstituted vaccine should be injected subcutaneously.
Reconstitute immediately prior to use by the addition of the contents of 1 vial (1,0 mℓ) of Nobivac® Diluent. The vaccine should be administered by subcutaneous injection in the neck or chest region, observing the usual aseptic precautions.
PRESENTATION
Polyethylene terephthalate (PET) tray containing 10 single dose vials of freeze-dried vaccine.
REGISTRATION HOLDER
Intervet South Africa (Pty) Ltd.
20 Spartan Road, Spartan,
1619, RSA
Tel: +27 (0) 11 923 9300
E-mail: msdahza@msd.com
www.msd-animal-health.co.za
DATE OF PUBLICATION OF THIS PACKAGE INSERT
20 August 2013
Zimbabwe Reg. No. E97/80.23.15/9465 Pharmaceutical Classification: 802315 Distribution Category: V.M.G.D. |